Mometasone controlled-release implant

Drug Profile

Mometasone controlled-release implant

Alternative Names: Bioabsorbable mometasone-eluting sinus implants - Intersect ENT; Mometasone furoate - Intersect; Mometasone furoate implant; Mometasone-eluting stent; Mometasone-releasing S8 sinus implant - Intersect ENT; NOVA sinus implant; PROPEL; PROPEL ContourTM; PROPEL mini; RESOLVE®; SINUVA; Steroid-releasing sinus implant

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intersect ENT
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnadienediols; Skin disorder therapies
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Sinusitis

Most Recent Events

  • 01 Oct 2017 Intersect ENT completes the phase III PROGRESS trial for Sinusitis (Frontal sinusitis) in USA (NCT02266810)
  • 09 Sep 2017 Pooled safety and efficacy data from the phase III RESOLVE and RESOLVE II trials in Sinusitis released by Intersect ENT
  • 22 May 2017 FDA assigns PDUFA action date of 07/01/2018 for Mometasone controlled release (SINUVA™) for Sinusitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top